TLR4 is emerging as a potential biomarker for new-onset AF following acute myocardial infarction, with significantly increased levels observed in patients experiencing new-onset AF compared to healthy controls and those with myocardial infarction alone (Zhang et al., 2018). Here, TLR4 is linked to atrial fibrillation.